Posted by Michael Wonder on 30 Jul 2020
Eton Pharmaceuticals submits new drug application to the FDA for zonisamide oral suspension (ET-104)
30 July 2020 - Application is Eton’s sixth drug application under FDA review.
Eton Pharmaceuticals today announced it has submitted a new drug application for zonisamide oral suspension, previously known as the company’s ET-104 product candidate, to the U.S. FDA for the treatment of partial seizures in patients with epilepsy.
